# Sight Sciences, Inc.: Form 10-Q for the period ended Mar 31, 2025

- Company: [Sight Sciences, Inc.](/companies/sght.md) (CIK 1531177)
- Form: 10-Q
- Filed: 2025-05-08
- Accepted by EDGAR: May 8, 2025, 20:16 ET
- Period: 2025-03-31
- Accession: 0000950170-25-067008
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1531177/000095017025067008/sght-20250331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1531177/000095017025067008/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-01-01 to 2025-03-31 | $17.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2025-01-01 to 2025-03-31 | $2.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2025-01-01 to 2025-03-31 | $15.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2025-01-01 to 2025-03-31 | $4.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2025-01-01 to 2025-03-31 | $24.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-01-01 to 2025-03-31 | −$13.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-01-01 to 2025-03-31 | $1.3m | us-gaap:InterestExpense |
| Income tax | 3 months, 2025-01-01 to 2025-03-31 | $41.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-01-01 to 2025-03-31 | −$14.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-01-01 to 2025-03-31 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-01-01 to 2025-03-31 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-01-01 to 2025-03-31 | 51,290,665 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2025-01-01 to 2025-03-31 | −$11.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2025-01-01 to 2025-03-31 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2025-03-31 | $108.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-03-31 | $126.9m | us-gaap:AssetsCurrent |
| Total assets | at 2025-03-31 | $129.7m | us-gaap:Assets |
| Current liabilities | at 2025-03-31 | $12.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-03-31 | $52.1m | us-gaap:Liabilities |
| Long-term debt | at 2025-03-31 | $39.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2025-03-31 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2025-03-31 | $77.6m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1531177/000095017025067008/sght-20250331.htm

Filed May 8, 2025.
Source: SEC EDGAR, the filing index for accession 0000950170-25-067008. Last ingested by Listed: Oct 24, 2026, 15:13 ET. No prices; not investment advice.